Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy

[1]  Na Kong,et al.  Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages , 2022, Nature Protocols.

[2]  Alan A. Chen,et al.  Structural and Binding Effects of Chemical Modifications on Thrombin Binding Aptamer (TBA) , 2021, Molecules.

[3]  Yuzhuo Wang,et al.  Molecular events in neuroendocrine prostate cancer development , 2021, Nature Reviews Urology.

[4]  Yiye Li,et al.  Multifunctional biomolecule nanostructures for cancer therapy , 2021, Nature Reviews Materials.

[5]  L. M. Valor,et al.  Targeting Protein Kinase C in Glioblastoma Treatment , 2021, Biomedicines.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  Jiashu Sun,et al.  A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis , 2021, Nature communications.

[8]  A. Shaw,et al.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.

[9]  Ying Xu,et al.  Molecular identification of protein kinase C beta in Alzheimer's disease , 2020, Aging.

[10]  Huile Gao,et al.  The progress and perspective of strategies to improve tumor penetration of nanomedicines , 2020 .

[11]  F. Ban,et al.  Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer , 2020, International journal of molecular sciences.

[12]  Yingfu Li,et al.  Evolution of a highly functional circular DNA aptamer in serum , 2020, Nucleic acids research.

[13]  E. Sabina,et al.  A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. , 2020, Life sciences.

[14]  E. Du,et al.  TACC3 promotes prostate cancer cell proliferation and restrains primary cilium formation. , 2020, Experimental cell research.

[15]  R. Montironi,et al.  Epigenetic modulations and lineage plasticity in advanced prostate cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Roskoski Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. , 2019, Pharmacological research.

[17]  Chunxiao Wu,et al.  SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer , 2019, Laboratory Investigation.

[18]  T. Graeber,et al.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.

[19]  Liang Cheng,et al.  LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling , 2019, Nature Communications.

[20]  P. Laakkonen,et al.  Octreotide Conjugates for Tumor Targeting and Imaging , 2019, Pharmaceutics.

[21]  Christian M. Metallo,et al.  Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. , 2019, Cancer cell.

[22]  Jun Zhu,et al.  Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma , 2019, Journal of Experimental & Clinical Cancer Research.

[23]  Zhihong Zhang,et al.  Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress. , 2019, Carcinogenesis.

[24]  K. Noguchi,et al.  Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells. , 2018, Biochemical and biophysical research communications.

[25]  Kinam Park Combined therapy of imatinib and an anti-CTLA4 immune-checkpoint inhibitor. , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[27]  Elkin Navarro-Quiroz,et al.  ELAC (3,12‐di‐O‐acetyl‐8‐O‐tigloilingol), a plant‐derived lathyrane diterpene, induces subventricular zone neural progenitor cell proliferation through PKCβ activation , 2017, British journal of pharmacology.

[28]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[29]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[30]  P. Jurasz,et al.  The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival , 2015, Journal of thrombosis and haemostasis : JTH.

[31]  Y. Zhang,et al.  The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials , 2015, Clinical and Translational Oncology.

[32]  Jeffrey A Jones,et al.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. , 2014, Blood.

[33]  S. Szymczak,et al.  Genomewide RNAi screen identifies protein kinase Cβ and new members of mitogen‐activated protein kinase pathway as regulators of melanoma cell growth and metastasis , 2014, Pigment cell & melanoma research.

[34]  G. Bepler,et al.  Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers , 2013, Cancer.

[35]  Y. Katayama,et al.  Protein kinase C (PKC) isozyme-specific substrates and their design. , 2012, Biotechnology advances.

[36]  V. Heinemann,et al.  A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer , 2012, Cancer.

[37]  M. Carducci,et al.  Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics , 2012, Investigational New Drugs.

[38]  A. Ganeshpurkar,et al.  Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog , 2012, Drug delivery.

[39]  H. Allgayer,et al.  Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules , 2010, British Journal of Cancer.

[40]  O. Franco,et al.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.

[41]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[42]  C. Collins,et al.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. , 2017, European urology.